News Category: News and Insights

HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company

[Utrecht, July 18 2023] — HUB Organoids (HUB), the global leader in the field of patient-derived organoids, is excited to announce a...

HUB Organoids extends partnership with Molecular Devices to advance automated intestinal organoid screening technology

SAN JOSE, Calif., and UTRECHT, Netherlands, Feb. 13, 2023 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, and...

HUB Organoids take their first parabolic flight!

FDA Modernization Act 2.0: We welcome the dawn of an organoid era

Imagine Reducing the Time to Identify a Drug

Patients with mutated KRAS (Kirsten rat sarcoma virus) gene account for around 30-50% of the population with colorectal cancer (CRC) and do...

Exclusive interview with Dr Carla Verissimo

Our Carla Verissimo, Head of Oncology II speaks about the current challenges of oncology drug development in this exclusive interview of the...

New PERSIST-SEQ program launched

2 September 2021, Utrecht (The Netherlands) - Hubrecht Organoid Technology (HUB) joins a new international consortium of academic and industrial leaders in...

Link revealed between HBV infection and liver cancer

HUB Organoids derived from patients with chronic hepatitis B show the first molecular signs of liver cancer. The molecular events that drive...

New service partnership

VANCOUVER, British Columbia - STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use...

CF models for drug development

HUB Organoids™ supports the on-going clinical evaluation of ELX-02 as a therapeutic agent for cystic fibrosis (CF). HUB Organoids™ advance treatment for...